Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

The bioenergetic deficits observed in Amyotrophic Lateral Sclerosis result from the disruption of mitochondria-associated ER membranes. Here, the authors show that this disruption impairs the use ...

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...

Ancient viral DNA embedded in the human genome has been linked to the genetic risks of certain neurodegenerative diseases, ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Amyotrophic Lateral Sclerosis [ALS] is a type of disorder ... there is still a chance for this program to have a pathway forward. How so? Well, the reason is that the company still has to do ...

Past studies have suggested that abnormal HERV activity may be linked to diseases like Alzheimer’s, multiple sclerosis, amyotrophic lateral sclerosis ... and cellular pathways remain unclear ...

"Clene plans to include the additional data in an NDA submission under the accelerated approval pathway in mid ... including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis.

China’s health regulator gave conditional approval to Platinum Life Excellence Biotech Co. Ltd.’s amimestrocel injection (hUC-MSC PLEB-001, Ruibosheng) as the nation’s first human umbilical ...